Lenvatinib 10mg capsules | Lenvatinib | Millionpharma

1
Lenvatinib 10mg capsules Lenvatinib
Millionpharma
2
DESCRIPTION

• Lenvatinib 10mg is a multi-kinase inhibitor and
  antineoplastic agents. It is a type of targeted
  treatment which target the specific cancer cells
  and hence reduces side effects caused by affected
  cells.Lenvatinib 10mg tablet inhibits the
  protein which promotes cell division by
  preventing the cancer cell development.

3
(No Transcript)
4
PRESCRIBED FOR

• In adult,Lenvatinib 10mg is indicated for the
  treatment of metastatic, progressive, radioactive
  Differentiated Thyroid cancer.
• Lenvatinib 10mg in combination with everolimus is
  indicated in patients for the treatment of
  advance Renal Cell Carcinoma following treatment
  before anti-angiogenic therapy.
• Lenvatinib 10mg tablet is also indicated for the
  first line treatment in patients suffering with
  unresectable hepatocellular carcinoma.

5
(No Transcript)
6
MECHANISM OF ACTION

• Lenvatinib is a tyrosine kinase inhibitor which
  has shown mainly anti-angiogenic properties, and
  direct prevention of malignant developed was also
  observed inside the models. Lenvatinib which
  selectively prevents the kinase functions of
  vascular endothelial growth factor receptors
  1(FLT1), 2 (KDR), 3 (FLT4).

7
MECHANISM OF ACTION

• Although not been studied directly with
  Lenvatinib 10mg, the mechanism of action (MOA)
  for High blood pressure is hypothesizing to be
  resolve by the prevention of VEGFR2 in vascular
  endothelial cells. Same as the, the action for
  proteinuria is hypothesizing to be interfere with
  down regulation of VEGFR1 and VEGFR2 in the cell
  of bowmans capsules of the glomerulus.

8
(No Transcript)
9
PROPERTIES

• Ingredients  Lenvatinib 
• Strength  10mg 
• Package  Pack of 20 Capsules.

10
ADME

• Absorption Time to high plasma concentration is
  1-4 hours post dose. Effect with food is low to
  the extent Lenvatinib 10mg of absorption.
• Distributionbounding of Human plasma proteins
  is 98 to 99.

11

• MetabolismLenvatinib 10mg is primarily
  metabolized in CYP3A. Lenvatinib 10mg metabolic
  pathway is identified as enzymatic and
  non-enzymatic processes.
• Elimination eliminated via 64 feces and 25
  urine.

12
DOSAGE MANAGEMENT

• The usual dose of Lenvatinib for the adult
  patients is 24mg and administer has two 10mg
  capsules and one 4mg capsule given orally, once
  daily taken with or without food.The Lenvatinib
  tablet should continue until disease progression
  or until unacceptable toxicity occurs.

13

• Take Lenvatinib 10mg tablet at the same
  time.Patients with severe renal or hepatic
  impairment the dose is 14mg administer once daily
  orally.
• OVERDOSE Lenvatinib is not expected to be
  dialyzable because of maximum plasma protein
  binding and if the dose getting of Lenvatinib
  10mg orally then causes death due to multiorgan
  dysfunction occurred in the patients.

14
PRECAUTIONS

• Blood pressure may increase while treatment
  with Lenvatinib 4mg. Your doctor will preferably
  check your blood pressure during your treatment.
• Inform the doctor if you are allergic
  to Lenvatinib 10mg, any other regimens, or any of
  the ingredients in Lenvatinib 10mg capsules. 
• Other prescription and nonprescription
  medications, vitamins, nutritional supplements,
  and herbal products you are taking or plan to
  take. Your doctor may to change the doses of your
  drugs or guide carefully for adverse reaction.

15
(No Transcript)
16

• Inform doctor if you have or had seizures,
  hypertension, a stroke, a heart attack, ,
  especially those due to blood clots, a fistula, a
  tear in the wall of your GIT, QT interval
  prolongation (an irregular heart rhythm that can
  lead to fainting, loss of consciousness,
  seizures, or sudden death), low levels of Ca, K
  or Mg in your blood, bleeding problems, or
  cardiac, renal, or hepatic disease.

17

• Take into the knowledge that Lenvatinib 10mg may
  reduce the fertility in men and women. It not
  means that you or your partner cannot become
  pregnant. Inform doctor before if you are
  pregnant or plan to become pregnant. After
  becoming pregnant, you should use birth control
  while treatment with Lenvatinib 10mg and for at
  least 2 weeks after your treatment, become
  pregnant during Lenvatinib therapy, call your
  doctor immediately. Lenvatinib 10mg may harm the
  fetus.

18

• Inform the doctor if you are breastfeeding or
  plan to breastfeed. Avoid breastfeed
  during Lenvatinib 10mg treatment.

19
SIDE EFFECTS

• Common side effectsTirednessPeeling of skin on
  palms and sole of the feetConstipationLoss of
  appetiteWeight lossJoint and muscle
  painInsomnia.

20
SIDE EFFECTS

• Serious side effects Shortness of breathChest
  painPain in arm, back, neck or
  jawSeizures Black, tarry or bloody stoolsHeavy
  menstrual bleedingCoughing up bloodYellowing of
  the skin or eyes.

21

• PREGNANCY
• When administrated to pregnant, Lenvatinib
  10mg drugs can cause harm to the fetal. There are
  no available human data related to drug
  associated risk. Advice pregnant women specific
  risk to fetus.
• LACTATION
• Excretion in human milk is unknown. Its not
  known that drug is present in human milk Because
  of the serious side effects in infants from the
  drug, Advice to avoid breast feeding during
  treatment with Lenvatinib 10mg.
• STORAGE
• Store at 25CKeep out of the children hands
  Discard the after-expiry date Dispense the drug
  only in original container

22
CONTACT US

• EMAIL millionhealthpharmaceuticals_at_gmail.
  com
• PHONE NO 91-9940472902 
• WEBSITE https//millionpharma.com/lenvatinib-10mg
  .php

23
(No Transcript)